Spots Global Cancer Trial Database for Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Official Title: Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)：a Prospective, Single-arm, Phase II Clinical Study
Study ID: NCT06251492
Study Description
Brief Summary: The aim of this study is to evaluate the efficacy of 2 cycles of combinatory adebrelimab and stereotactic radiotherapy, followed by monotherapy adebrelimab in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Fujian Cancer Hospital, Fuzhou, Fujian, China
Fudan University Shanghai Cancer Center Xiamen Branch., Xiamen, Fujian, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
